🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07377175
Recruiting Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

NCT07377175 · tracked via the Priya Life Science China tracker
Sponsor
China National Biotec Group Company Limited
Phase
Phase 1
Started
2025-08-28
Last updated
2026-01-29

Condition(s) studied

SmallpoxCowpoxMonkeypoxPoxvirus Infection

Investigational drug(s) / intervention(s)

BSY001 for Injection (37.5mg)BSY001 for Injection (75 mg)BSY001 for Injection (150 mg)BSY001 for Injection (200 mg)BSY001 for Injection (300 mg)placebo-SADBSY001 for Injectionplacebo-MAD

BSY001 for Injection (37.5mg): A single dose of 37.5mg BSY001 for injection.

BSY001 for Injection (75 mg): A single dose of 75 mg BSY001 for injection.

BSY001 for Injection (150 mg): A single dose of 150 mg BSY001 for injection.

BSY001 for Injection (200 mg): A single dose of 200 mg BSY001 for injection.

BSY001 for Injection (300 mg): A single dose of 300 mg BSY001 for injection.

placebo-SAD: A single dose for injection.

BSY001 for Injection: Administer 200 mg of BSY001 every 12 hours for 14 consecutive days.

placebo-MAD: Administer placebo every 12 hours for 14 consecutive days.

Study summary

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Subjects voluntarily participate in the study, sign the informed consent form, and agree to comply with all study requirements; 2. Aged ≥ 18 years and ≤ 50 years (based on the date of signing the informed consent form), including both males and females; 3. Body Mass Index (BMI) between 19.0 and 30.0 kg/m² (19.0 and 30.0 kg/m² inclusive); for female subjects, body weight between 45.0 and 120.0 kg (45.0 kg inclusive and 120.0 kg exclusive); for male subjects, body weight between 50.0 and 120.0 kg (50.0 kg inclusive and 120.0 kg exclusive); 4. Subjects (including their partners) voluntarily adopt effective contraceptive measures from 1 month before screening to 6 months after the last administration of the study drug, and have no plans for childbearing, sperm donation, or egg donation within the next 6 months. Exclusion Criteria: 1. Subjects with a known allergy to Tecovirimat drugs, any excipient ingredients in this product, or subjects with an allergic diathesis (allergic to ≥ 2 types of substances); 2. Subjects with clinically significant abnormal electrocardiogram (ECG) findings or QTc prolongation as determined by the investigator (e.g., QTc interval ≥ 450 ms in males and ≥ 470 ms in females, with QTc interval calculated using the Fridericia formula); 3. Subjects with a creatinine clearance rate (Cockcroft-Gault formula) \< 90 mL/min; 4. Subjects with clinically significant abnormalities in physical examination, vital signs, laboratory tests, or other auxiliary examinations as determined by the investigator; 5. Subjects with current or past history of the following clinically significant diseases as determined by the investigator, including but not limited to diseases of the cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, immune system, and nervous system (e.g., epilepsy); 6. Subjects with a current or history (within the past 3 months) of bacterial, fungal, or mycobacterial infection.; 7. Subjects with known clinically significant acute/chronic viral infections; 8. Subjects with a history of severe headache or migraine; 9. Subjects who have undergone major surgery within 6 months before drug administration, or plan to undergo surgery from the time of signing the informed consent form to 1 month after the end of the trial; 10. Subjects who have donated blood or had massive blood loss (\> 450 mL) within 3 months before screening; 11. Subjects who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form, or cannot refrain from using any tobacco products during the trial; 12. Subjects who consumed more than 14 units of alcohol per week within 3 months before signing the informed consent form (1 unit of alcohol ≈ 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine), had a positive alcohol breath test (breath alcohol content \> 0 mg/100 mL), or cannot abstain from alcohol during the trial; 13. Subjects who consumed grapefruit, grapefruit juice, chocolate, strong tea, coffee, or other beverages containing caffeine or alcohol within 72 hours before drug administration, or refuse to stop consuming the aforementioned beverages and foods during the trial; 14. Subjects who plan to engage in strenuous exercise during the trial, including contact sports or collision sports; 15. Subjects with a positive urine drug screen (for morphine, methamphetamine, ketamine, 3,4-methylenedioxymethamphetamine, or tetrahydrocannabinolic acid), or a history of drug abuse or drug use within 5 years before screening; 16. Subjects with a positive result in any of the following tests: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (IgG), hepatitis C virus core antigen, human immunodeficiency virus (HIV) antibody, or treponema pallidum-specific antibody (TP-Ab); 17. Subjects who participated in other drug clinical trials within 3 months before screening (calculated starting from the time of the last drug administration in the previous trial); 18. Subjects who took any prescription drugs, over-the-counter drugs, or traditional Chinese herbal medicines within 30 days before screening; 19. Subjects with a positive pregnancy test result; 20. Subjects who cannot tolerate venipuncture, or have a history of hematophobia (fear of blood) or trypanophobia (fear of needles); 21. Subjects who developed an acute illness or required concomitant medication from the screening phase to before the first drug administration; 22. Subjects who received a vaccine within 2 weeks before screening, or plan to receive a vaccine during the trial; 23. Subjects deemed unsuitable for participation in this trial by the investigator.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shulan (Hangzhou) Hospital Hangzhou China Recruiting

More China National Biotec Group Company Limited trials in China

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Active, not recruiting
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines Starting soon

Other trials for the same condition

A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07377175 on ClinicalTrials.gov ↗ ← All trials in China